Linked Life Data

10817719

Source:http://linkedlifedata.com/resource/pubmed/id/10817719

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2000-7-11
pubmed:abstractText
Nikkomycin Z was tested both in vitro and in vivo for efficacy against Histoplasma capsulatum. Twenty clinical isolates were tested for susceptibility to nikkomycin Z in comparison to amphotericin B and itraconazole. The median MIC was 8 microg/ml with a range of 4 to 64 microg/ml for nikkomycin Z, 0.56 microg/ml with a range of 0.5 to 1.0 microg/ml for amphotericin B, and < or =0.019 microg/ml for itraconazole. Primary studies were carried out by using a clinical isolate of H. capsulatum for which the MIC of nikkomycin Z was greater than or equal to 64 microg/ml. In survival experiments, mice treated with amphotericin B at 2.0 mg/kg/dose every other day (QOD) itraconazole at 75 mg/kg/dose twice daily (BID), and nikkomycin Z at 100 mg/kg/dose BID survived to day 14, while 70% of mice receiving nikkomycin Z at 20 mg/kg/dose BID and none of the mice receiving nikkomycin Z at 5 mg/kg/dose BID survived to day 14. All vehicle control mice died by day 12. Fungal burden was assessed on survivors. Mice treated with nikkomycin Z at 20 and 100 mg/kg/dose BID had significantly higher CFUs per gram of organ weight in quantitative cultures and higher levels of Histoplasma antigen in lung and spleen homogenates than mice treated with amphotericin B at 2.0 mg/kg/dose QOD or itraconazole at 75 mg/kg/dose BID. Studies also were carried out with a clinical isolate for which the MIC of nikkomycin Z was 4 microg/ml. All mice treated with amphotericin B at 2.0 mg/kg/dose QOD; itraconazole at 75 mg/kg/dose BID; and nikkomycin Z at 100, 20, and 5 mg/kg/dose BID survived until the end of the study at day 17 postinfection, while 30% of the untreated vehicle control mice survived. Fungal burden assessed on survivors showed similar levels of Histoplasma antigen in lung and spleen homogenates of mice treated with amphotericin B at 2.0 mg/kg/dose QOD; itraconazole at 75 mg/kg/dose BID; and nikkomycin Z at 100, 20, and 5 mg/kg/dose BID. The three surviving vehicle control mice had significantly higher antigen levels in lung and spleen than other groups (P<0.05). The efficacy of nikkomycin Z at preventing mortality and reducing fungal burden correlates with in vitro susceptibility.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10817719-2344165, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817719-2393272, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817719-3171821, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817719-4051311, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817719-7826015, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817719-8083179, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817719-8164105, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817719-8406857, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817719-9276396, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817719-9303408, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817719-9352737, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817719-9736565, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817719-9925526
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1624-9
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model.
pubmed:affiliation
Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
pubmed:publicationType
Journal Article, Comparative Study